Corcept Therapeutics Incorporated (CORT)
| Market Cap | 12.66B +73.2% |
| Revenue (ttm) | 830.81M +16.0% |
| Net Income | 54.27M -58.7% |
| EPS | 0.45 -59.3% |
| Shares Out | 108.10M |
| PE Ratio | 257.86 |
| Forward PE | 29.32 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 140,418 |
| Open | 114.20 |
| Previous Close | 113.98 |
| Day's Range | 113.77 - 117.38 |
| 52-Week Range | 28.66 - 126.38 |
| Beta | 0.45 |
| Analysts | Buy |
| Price Target | 141.00 (+20.42%) |
| Earnings Date | Jul 29, 2026 |
About CORT
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortis... [Read more]
Financial Performance
In 2025, Corcept Therapeutics's revenue was $761.41 million, an increase of 12.79% compared to the previous year's $675.04 million. Earnings were $98.17 million, a decrease of -29.74%.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for CORT stock is "Buy." The 12-month stock price target is $141.0, which is an increase of 20.42% from the latest price.
News
Corcept Therapeutics assumed with a Buy at Truist
Truist assumed coverage of Corcept Therapeutics (CORT) with a Buy rating with a price target of $164, up from $50. The form is positive on the company’s opportunity in Cushing’s,…
Raised Guidance Lifts Corcept to 52-Week High
CORT discovers, develops, and sells medications to treat severe metabolic, oncologic, and psychiatric disorders, focusing on the hormone cortisol (over 1,000 proprietary modulators) as well as Cushing...
Corcept Therapeutics price target raised to $161 from $150 at Canaccord
Canaccord analyst Edward Nash raised the firm’s price target on Corcept Therapeutics (CORT) to $161 from $150 and keeps a Buy rating on the shares. The firm said Corcept reported…
Corcept Therapeutics price target raised to $165 from $88 at Piper Sandler
Piper Sandler raised the firm’s price target on Corcept Therapeutics (CORT) to $165 from $88 and keeps an Overweight rating on the shares. The firm notes Corcept reported Q2 diluted…
Corcept Therapeutics price target raised to $165 from $95 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Corcept Therapeutics (CORT) to $165 from $95 and keeps a Buy rating on the shares. The firm says Lifyorli’s “rapid ramp” and…
Corcept Therapeutics Earnings Call Transcript: Q2 2026
Q2 2026 revenue grew 32% year-over-year to $256.1 million, driven by strong launches in both endocrinology and oncology. LIFYORLI saw rapid uptake with over 1,300 patients treated, and guidance was raised to $1.1–$1.2 billion for 2026.
Corcept Therapeutics Earnings release: Q2 2026
Corcept Therapeutics released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
Corcept Therapeutics Quarterly report: Q2 2026
Corcept Therapeutics has published its Q2 2026 quarterly earnings report on July 29, 2026.
Corcept Therapeutics reports Q2 EPS 36c, consensus 5c
Reports Q2 revenue $256.1M, consensus $220.1M. “Our oncology and Cushing’s syndrome businesses delivered strong results in the second quarter. In our oncology business, over 1,300 patients have now st...
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept Therapeutics price target raised to $150 from $135 at Canaccord
Canaccord analyst Edward Nash raised the firm’s price target on Corcept Therapeutics (CORT) to $150 from $135 and keeps a Buy rating on the shares. The firm updated its model…
Corcept Therapeutics downgraded to Underperform from Peer Perform at Wolfe Research
Wolfe Research downgraded Corcept Therapeutics (CORT) to Underperform from Peer Perform with a $50 price target The firm expects Lifyorli sales to exceed the “low” Q2 bar and build into…
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on July 29, 2026....
Corcept Therapeutics resubmits NDA for Relacorilant in Cushing’s Syndrome
The company states: “Corcept Therapeutics (CORT) announced it has resubmitted its New Drug Application to the U.S. Food and Drug Administration for relacorilant as a treatment for patients with Cushin...
Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept announces presentation of new data from Catalyst, Momentum trials
Corcept Therapeutics (CORT) announced the presentation of new data from its Catalyst and Momentum trials at the American Diabetes Association’s 86th Scientific Sessions. The presentations underscore t...
Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept Therapeutics price target raised to $135 from $110 at Canaccord
Canaccord raised the firm’s price target on Corcept Therapeutics (CORT) to $135 from $110 and keeps a Buy rating on the shares. The firm Corcept surprised today in reporting they…
Corcept Therapeutics price target raised to $95 from $75 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Corcept Therapeutics (CORT) to $95 from $75 and keeps a Buy rating on the shares. The firm cites the…
Corcept Therapeutics to resubmit NDA to U.S. FDA for relacorilant
Corcept Therapeutics (CORT) announced it will resubmit its New Drug Application, NDA, to the U.S. Food and Drug Administration, FDA, for relacorilant as a treatment for patients with Cushing’s syndrom...
Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept Therapeutics upgraded to Buy from Neutral at UBS
UBS upgraded Corcept Therapeutics (CORT) to Buy from Neutral with a price target of $72, up from $44. The recent approval of Lifyorli in ovarian cancer is expected to drive…
Corcept Therapeutics upgraded to Buy from Neutral at UBS
UBS upgraded Corcept Therapeutics (CORT) to Buy from Neutral with a $72 price target
Corcept Therapeutics Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 4.9% year-over-year to $164.9M, but net loss reached $31.8M due to launch costs. Lifyorli’s early FDA approval and rapid adoption, plus strong endocrinology growth, led to raised 2026 guidance of $950M–$1.05B.
Corcept Therapeutics Earnings release: Q1 2026
Corcept Therapeutics released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.